now have 15% of company as reward lined up and if they are there just to get shareholders hyped up at the prospect of tripling the SP then it is the sort of management of expectation that is out of favour. This is a company whose product is needed and sells itself without management pretending they deserve a global magnate size remuneration. The company just needs steady organic growth not a tripling of prospects in two years.
Plant Impact, the agricultural crop improvement specialist, said it now expects to break even after trading profitably through the last full year. After a transformational year to the end of July, the AIM-listed company predicted growth for the 2016 financial year on the back of substantial sales in Brazil of its soybean crop efficiency product, Veritas.
Sales of Veritas, which is sold in Brazil by German multinational Bayer, were encouraging and helped group revenue expand 80% to £4.5m, of which £1.4m came in the fourth quarter, itself a 75% increase.
Although sales in Northern Europe were hit by Russia's boycott of European produce, Plant Impact said overall for the year its net profit after tax was expected to be £0.1m, reversing the previous year's £0.7m loss.
Chief executive John Brubaker said it had been a transformational year for the group and said 2016 was "an important year for multiple growth programmes".
"The directors have a positive sales outlook for the 2016 financial year."
This is predicated on forecasts of "substantial growth" in Brazil for Veritas as sales are expanded across the whole country after a successful test-marketing season, with firm orders already received for most of its expected sales in the 2015/16 Brazilian soybean season.
Northern Europe, the smaller region from a current sales perspective, is expected to see "modest" growth, Middle-Eastern sales are expected to continue to expand, and a first commercial year of Banzai, a new product to improve cocoa yield that will be marketed in West Africa by Arysta LifeScience, beginning with Cameroon and the Ivory Coast.
Management also plan to significantly expand commercial and research and development programmes, using some of the £7.6m cash balances.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.